LUGPA 2025 CME Enduring Program: Operationalizing the Science -Translating New Concepts into Clinical Practice-2025 CME Program Part 9

Video Transcription

Video Summary

Dr. Jeffrey Speer discusses operationalizing radioligand therapies in independent urology practices, emphasizing theranostics as both a clinical innovation and strategic business model. He highlights the design and workflow considerations for integrating advanced molecular imaging and targeted therapies sustainably within private practices. Speer underscores the importance of multidisciplinary partnerships, revenue operations, compliance, and quality patient care to successfully implement radioligand therapy. <br /><br />Dr. Oto from the University of Chicago provides an in-depth overview of prostate MRI, focusing on prostate anatomy, the PI-RADS scoring system, and common diagnostic pitfalls. He explains the differences in imaging characteristics across prostate zones and illustrates how to interpret multiparametric MRI features for cancer detection. Oto discusses challenges such as prostatitis, hemorrhage, and focal atrophy that can mimic cancer, stressing the need for high-quality imaging and collaboration between radiologists and urologists. He also points to emerging quantitative MRI techniques and AI tools aimed at improving diagnostic accuracy. Both presentations emphasize integrating advanced imaging and therapies into clinical practice for improved prostate cancer care.

Keywords

radioligand therapy

theranostics

prostate MRI

PI-RADS scoring system

multiparametric MRI

prostate cancer diagnostics